VF
RANI icon

Virtu Financial’s Rani Therapeutics RANI Stock Holding History

Virtu Financial’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,178
Closed -$69K – 2179
2025
Q4 		$69K Buy
+51,178
New +$77.2K ﹤0.01% 1266
2025
Q1 		– Sell
-45,404
Closed -$62K – 1921
2024
Q4 		$62K Buy
+45,404
New +$95.4K ﹤0.01% 1119
2024
Q3 		– Sell
-10,153
Closed -$39K – 1802
2024
Q2 		$39K Buy
+10,153
New +$52.6K ﹤0.01% 939

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Virtu Financial's RANI Position: Q1 2026 in Review

Virtu Financial sold out of Rani Therapeutics (RANI) in Q1 2026, closing a stake of 51,178 shares — an estimated $69K sold.

Virtu Financial first reported a position in RANI in Q2 2024 and held it in 3 quarters. The position peaked at $69K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Virtu Financial reported no remaining Rani Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 51,178 Rani Therapeutics shares in Q1 2026, an estimated $69K.
  • Virtu Financial first reported a position in Rani Therapeutics in Q2 2024 and held it in 3 quarters.
  • Virtu Financial's Rani Therapeutics position peaked at $69K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.